相关实验视频

Updated: Jun 3, 2025

Expression of Exogenous Antigens in the Mycobacterium bovis BCG Vaccine via Non-genetic Surface Decoration with the Avidin-biotin System

Expression of Exogenous Antigens in the Mycobacterium bovis BCG Vaccine via Non-genetic Surface Decoration with the Avidin-biotin System

Published on: January 31, 2018

一个BoHV-1gG-/tk-疫苗的增强免疫性

Sen Zhang¹, Guoxing Liu¹, Chen Wang¹

¹National Key Laboratory of Agricultural Microbiology, Hubei Hongshan Laboratory, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China; Hubei International Scientific and Technological Cooperation Base of Veterinary Epidemiology, the Cooperative Innovation Center for Sustainable Pig Production, Wuhan 430070, China.

|January 8, 2025

概括

一种新型牛疹病毒1型 (BoHV-1) gG-/tk-基因被删除的疫苗,与无活化疫苗相比,在牛群中提供了更好的保护和免疫反应. 这种BoHV-1疫苗显示出市场应用的巨大潜力.

科学领域:

兽医病毒学兽医病毒学
免疫学免疫学免疫学
疫苗开发疫苗开发

背景情况:

牛疹病毒1型 (BoHV-1) 在全球范围内引起牛的严重呼吸道疾病.
此前在中国开发了一种针对BoHV-1的新型双基因删除疫苗 (gG-/tk).

研究的目的:

为了评估BoHV-1 gG-/tk-基因删除疫苗的疗效.
为了比较其性能与商业无活化BoHV-1疫苗.
评估对普遍存在的野生型BoHV-1菌株的保护.

主要方法:

用被删除基因的疫苗或失活的疫苗接种牛的疫苗.
挑战与野生类型的BoHV-1.
监测临床症状,直肠温度和免疫标记物 (IFN-γ,TNF-α).
测量中和抗体和特定的gB抗体.
评估病毒分泌和执行肺组织组织学.

主要成果:

所有接种疫苗的群体在挑战后都保持了临床健康.
被删除基因的疫苗增强了IFN-γ和TNF-α的表达.
在免疫群体中观察到高中和gB抗体标位.
在接种疫苗的牛群中显著减少病毒流放和改善肺组织完整性.
删除gG/tk基因的疫苗显示了更高的保护率.

结论:

删除BoHV-1 gG-/tk-基因的疫苗提供了强大的保护和卓越的免疫性.
它的性能优于经过测试的非活化疫苗.
这种疫苗显示出未来在牛健康领域市场应用的巨大潜力.

关键词:

这种病毒是BoHV-1病毒.基因被删除的疫苗免疫性免疫性免疫性不活化的BoHV-1疫苗

更多相关视频

Determination of Vaccine Immunogenicity Using Bovine Monocyte-Derived Dendritic Cells

Determination of Vaccine Immunogenicity Using Bovine Monocyte-Derived Dendritic Cells

Published on: May 19, 2023

Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector

Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector

Published on: November 28, 2018

相关概念视频

Vaccinations

Vaccinations

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...